Abstract: Lymphoma, encompassing Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), is a prevalent cancer worldwide. Chemotherapy is the favored treatment for lymphoma. With the ongoing implementation of innovative drugs and technologies, the incidence of typical post-chemotherapy adverse effects, such as cardiotoxicity and bone marrow suppression, has reduced, while the incidence of some previously rare complications is gradually increasing. Of them, interstitial pneumonia (IP) is a fatal post-chemotherapy complication in patients with lymphoma. It can cause difficulty in breathing, respiratory failure, and death. Furthermore, patients with IP experience longer treatment delays and a higher frequency of premature chemotherapy termination. IP pathogenesis is not well understood; therefore, the management of IP is challenging. This article aims to summarize the latest research advancements in China and abroad and review the mechanism of occurrence, clinical manifestations, risk factors, diagnostic methods, and treatment options for IP complicated by lymphoma treatment.